Valuation: Simulations Plus, Inc.

Market Cap 370M 321M 299M 275M 519M 35.33B 528M 3.53B 1.38B 17.55B 1.39B 1.36B 59.02B P/E 2026 *
43.6x
P/E 2027 * 40x
Enterprise Value 370M 321M 299M 275M 519M 35.33B 528M 3.53B 1.38B 17.55B 1.39B 1.36B 59.02B EV / Sales 2026 *
4.52x
EV / Sales 2027 * 4.29x
Free-Float
83.08%
Yield 2026 *
-
Yield 2027 * -
1 day+0.03%
1 week-0.14%
Current month+0.03%
1 month-0.19%
3 months+22.84%
6 months+9.21%
Current year+0.47%
1 week 18.3
Extreme 18.3
18.39
1 month 18.19
Extreme 18.19
18.47
Current year 11.09
Extreme 11.09
21.01
1 year 11.09
Extreme 11.09
21.01
3 years 11.09
Extreme 11.09
52.69
5 years 11.09
Extreme 11.09
67.59
10 years 7.9
Extreme 7.9
90.92
Manager TitleAgeSince
Chief Executive Officer 67 26/06/2018
Director of Finance/CFO 63 01/12/2020
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Chairman 81 17/07/1996
Director/Board Member 58 03/12/2014
Chairman 76 17/12/2024
Date Insider Type Main position Quantity % Market Cap.
7/6/26 A Sell

Executive/Senior Manager

-1,000 0.0050%
7/1/26 A Sell

Founder

-4,177 0.0207%
6/15/26 A Fiscal year

Executive/Senior Manager

3,150 0.0156%
Change 5-day change 1-year change 3-year change Capi.($)
+0.03%-0.14%+40.67%-63.22% 370M
+0.09%+8.69%-28.78%-0.88% 32.74B
+0.94%+0.05%-49.27%+134.14% 11.77B
-3.76%+1.05%-26.01%+59.31% 5.63B
-1.57%+5.47% - - 2.23B
-2.06%-11.66%+16.80%-42.64% 1.69B
-0.78%+3.81% - - 1.8B
+3.26%-1.16%-34.17% - 1.01B
-2.27%-2.17%+30.64%+97.47% 871M
+6.25%+7.85%-38.34%-51.63% 770M
Average -0.01%+1.40%-11.06%+18.93% 5.89B
Weighted average by Cap. -0.16%+6.36%-30.31%+34.05%

Financials

2026 *2027 *
Net sales 81.87M 71.11M 66.04M 60.9M 115M 7.82B 117M 782M 306M 3.88B 307M 301M 13.05B 86.26M 74.92M 69.58M 64.17M 121M 8.23B 123M 824M 323M 4.09B 324M 317M 13.75B
Net income 9.53M 8.28M 7.69M 7.09M 13.36M 910M 13.6M 91.04M 35.65M 452M 35.8M 35.02M 1.52B 10.18M 8.84M 8.21M 7.57M 14.27M 972M 14.52M 97.22M 38.07M 483M 38.23M 37.4M 1.62B
Net Debt - -
Logo Simulations Plus, Inc.
Simulations Plus, Inc. specializes in model-informed and artificial intelligence (AI)-accelerated drug development. The Company helps its clients by accelerating the discovery, development, and commercialization of pharmaceuticals and other products through science-based software and consulting solutions. The Company’s segments include Software and Services. The Company's Software segment supports pharmaceutical research, development, and commercialization through simulation, modeling, and AI-driven prediction. Its main products include GastroPlus, ADMET Predictor, MonolixSuite, and others for disease modeling and training, as well as Pro-ficiency for clinical operations. Its Services segment includes advanced consulting services across the entire drug development lifecycle. Its scientists and engineers specialize in drug discovery, pharmacokinetics, pharmacodynamics, drug modeling, clinical trial data analysis, regulatory strategy, and medical communications.
Employees
213
Date Price Change Volume
31/07/26 $18.31 +0.03% 87,736
30/07/26 $18.30 -0.16% 215,369
29/07/26 $18.33 0.00% 346,154
28/07/26 $18.33 0.00% 158,846
27/07/26 $18.33 -0.05% 391,624
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
5
Last Close Price
18.30USD
Average target price
17.25USD
Spread / Average Target
-5.74%

Quarterly revenue - Rate of surprise